Shijiazhuang Pharmaceutical Group Receives EDQM Certification For Vitamin B12
This article was originally published in PharmAsia News
Shijiazhuang Pharmaceutical Group has gained an on-site inspection certification for its vitamin B12 from the European Directorate for the Quality of Medicines, making it the first in China's vitamin B12 industry. The endorsement will allow China-made vitamin B12 to enter the high-end pharmaceutical field in 34 countries for manufacturing and sale. The potential market expansion and economic benefit represents major progress for local products which hitherto got little profit from the feedstuff and food industry. To avoid vicious competition in the low-end market, Shijiazhuang Pharmaceutical recently stepped up its international certification and registration efforts; it has already received EU Certificate of Suitability for six products - vitamin C, vitamin B12, caffeine, ranitidine, theophylline and amoxicillin. (Click her for more - Chinese Language)
You may also be interested in...
The US FDA released five device-related close-out letters in March.
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.